Psychedelic Drugmaker Definium Surges on Depression Drug Success
Definium Therapeutics Inc. shares rally as much as 60% Monday after late-stage trial data showed “groundbreaking” results in the psychedelic drug developer’s experimental treatment for major depressive disorders.
By Avalon Pernell · Bloomberg Markets
Definium Therapeutics Inc. shares rally as much as 60% Monday after late-stage trial data showed “groundbreaking” results in the psychedelic drug developer’s experimental treatment for major depressive disorders.